

Hepatitis C in Primary Care & Drug and Alcohol Settings

Treating hepatitis C in people who inject drugs

People who inject drugs (PWID) represent approximately 90% of newly acquired hepatitis C (HCV) infections. Clinicians working with PWID play an important role in reducing HCV-related morbidity and mortality through early diagnosis and treatment.

With the advent of new, well-tolerated, short-course direct acting antiviral (DAA) HCV regimens with cure rates >95%, there is an opportunity to vastly improve the health outcomes of people living with HCV.

This course is designed for medical practitioners, nurses, addiction medicine specialists and other clinical staff working with people who inject drugs. Through online learning and a face-face workshop, delivered by local experts, participants will gain the skills to confidently manage hepatitis C in their setting.

At the conclusion of this program, participants will be able to:

- Describe the risk factors for HCV infection, enabling effective practice screening processes and prevention education
- Demonstrate competence interpreting clinical information to effectively diagnose HCV
- Demonstrate competence in liver disease assessment
- Demonstrate understanding of DAA therapy for the treatment of HCV and competence in selecting and prescribing appropriate therapy
- Monitor patients on treatment and post-treatment appropriately

Certification

This Group Learning program has been reviewed by the College of Family Physicians of Canada and is awaiting provincial certification by the College's ON Chapter.

About INHSU

This Symposium is convened by the International Network on Hepatitis in Substance Users (INHSU), an international organisation dedicated to scientific knowledge exchange, knowledge translation, and advocacy focused on hepatitis C prevention and care among people who use drugs.

Date:

Sunday, 24th November 2019 (8:30am - 4:00pm)

Venue:

Les Suites Hotel
130 Besserer Street
Ottawa, ON K1N 9M9, Canada

Cost:

The course is free of charge and fully catered. Places are limited - registration is essential.

Presenter:

Dr Curtis Cooper
Infectious Disease Physician;
Associate Professor at University of Ottawa;
Scientist at Ottawa Hospital Research Institute;
Director of the Ottawa Hospital Viral Hepatitis Program

Roselyn Castaneda

Registered Nurse;
Program Coordinator at The Ottawa Hospital and
Regional Hepatitis Program

Registration link:

<https://ashm.eventsair.com/ottawa-24-november-2019-hep-c/registration/Site/Register>

Register before:

Thursday, 14th November 2019

More information:

For further details contact
education@ashm.org.au

This workshop has been funded through an unrestricted grant from AbbVie Canada and Gilead Sciences Canada. AbbVie and Gilead have had no input into the tone, content or emphasis of the material used at this course.



ashm



UNSW
SYDNEY



Kirby Institute



CanHepC
Canadian Network on Hepatitis C
Réseau Canadien sur l'Hépatite C



Association Canadienne
pour l'étude du foie
ACEF



Canada's source for
HIV and hepatitis C
information